Stocklytics Platform
Asset logo for symbol IGMS
IGM Biosciences
IGMS51
$11.31arrow_drop_up10.12%$1.04
Asset logo for symbol IGMS
IGMS51

$11.31

arrow_drop_up10.12%
Key Stats
Open$9.41
Prev. Close$9.31
EPS-3.57
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range9.41
10.47
52 Week Range3.81
17.70
Ratios
EPS-3.57
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.91%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

IGMS-
US Healthcare Sector-
US Market-
warning

IGMS / Market

IGMS lose to the US Market which returned -1.01% over the last twenty four hours.
warning

IGMS / Healthcare Sector

IGMS lose to the US Healthcare sector which returned -0.54% over the last twenty four hours.

IGM Biosciences (IGMS) Statistics

IGM Biosciences Inc (IGMS) is a biotechnology company that focuses on developing engineered IgM antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and was founded in 2010. IGMS is traded on the NASDAQ stock exchange under the ticker symbol IGMS.
When it comes to stock statistics, IGMS has shown strong performance in recent years. As of the most recent data, the stock has a market capitalization of $2.5 billion and a price-to-earnings ratio of 37.3. This indicates that investors are willing to pay a premium for shares of IGMS due to its potential for future growth.
add IGM Biosciences  to watchlist

Keep an eye on IGM Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has IGM Biosciences (IGMS) stock's performance compared to its sector and the market over the past year?

Over the past year, IGM Biosciences (IGMS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.03%, IGM Biosciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.21%, it has fallen short of the market average. This comparison highlights IGM Biosciences 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of IGM Biosciences (IGMS) stock?

The PE ratio for IGM Biosciences (IGMS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of IGM Biosciences (IGMS) stock?

The Earnings Per Share (EPS) for IGM Biosciences (IGMS), calculated on a diluted basis, is -$3.57. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of IGM Biosciences (IGMS) stock?

The operating margin for IGM Biosciences (IGMS) is -4.1K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of IGM Biosciences (IGMS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of IGM Biosciences (IGMS) is -$226.37M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does IGM Biosciences (IGMS) have?

IGM Biosciences (IGMS) has a total debt of $39.37M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$27.89M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media